N/A N=35 Randomized Quadruple-blind Prevention

Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma

Colorectal Adenoma · Risk Reduction

Bottom Line

View on ClinicalTrials.gov: NCT01948661 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2024

Primary outcome: Primary: Change in Beta Catenin Expression — 100; 100; 100; 100 percentage of positive cells

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Mirtoselect® + Meriva® (Dietary_supplement); Placebo (Dietary_supplement)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Ente Ospedaliero Ospedali Galliera
Primary completion: Jan 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Beta Catenin Expression	100; 100; 100; 100; 100; 100	—
SECONDARY Change in Biomarkes Expression	36.7; 52.7; 42.3; 50.7; 69.7; 74.3	—

Summary

It has been shown that curcumin and cyanidin-3-glucoside (C3G) have anticancer effects. In this clinical trial we compare the affect of their combination vs placebo in a four weeks intervention before endoscopic polypectomy.

Eligibility Criteria

Inclusion criteria

Subjects with colorectal adenomatous polyps greater than 1 cm in maximum diameter not suitable to immediate complete removal;
Normal renal and hepatic function;
WHO Performance status=0;

Exclusion Criteria

Presence of hyperplastic polyps and/or flat adenomas;
Subjects with pre-existing colorectal cancer;
Presence of carcinomatous tissue in adenoma;

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01948661). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.